87% CHADS<span class='clean_sub'>2</span> ≥3 - Novel Oral Anticoagulants - Recent Advances in Oral Anticoagulation Therapy for Patients with Atrial Fibrillation

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 33

87% CHADS2 ≥3

An important characteristic of the ROCKET AF trial.[97] in distinction from the RE-LY trial,[96] was that the mean CHADS₂ score was higher (3.5) for both the rivaroxaban and warfarin arms. As a result, approximately 90% of the patients had a history of prior CNS embolism -- so re-emphasizing that the ROCKET AF population was a very sick group of patients.

Reiffel JA. Am J Med 2013; 126: 00-00.